Recursion Pharmaceuticals Inc., which uses machine learning to hunt for new therapies, raised $436 million in an upsized initial public offering (IPO) priced at the top of a marketed range. The Salt Lake City-based company sold about 24 million shares on Thursday for $18 each, according to data compiled by Bloomberg. The company, which marketed the shares for $16 to $18, twice earlier Thursday increased the number of shares to be sold.

• Orient Cables Eyes Rs 3,500 Crore Revenue By FY30
• Bangladesh Resumes Indian Wheat Purchases as Black Sea Disruptions Lift Prices
• Central Railway Recovers Rs 140 Crore In Ticket Fines
• Cosmic CRF Unit Bags Rs 25.94 Crore Combined Orders
• Arivihan in Talks to Raise Rs 96 Crore at Rs 570 Crore Valuation

Recursion reached a deal with Bayer AG in September to use AI to find new drugs for lung fibrosis and other fibrotic diseases. The deal included a $30 million upfront payment and $50 million in equity funding by Bayer’s investment arm. An investment arm of Bayer led a $239 million funding round for Recursion in September, according to a statement at the time. The company’s investors include Baillie Gifford and Mubadala, among others. The offering is being led by Goldman Sachs Group Inc. and JPMorgan Chase & Co. The shares are expected to begin trading Friday on the Nasdaq Global Select Market under the symbol RXRX.